Screening for atrial fibrillation (AF) using a wearable heart monitor for 2 weeks can identify older adults with this potentially dangerous abnormal heart rhythm, but does not prevent subsequent strokes, according to late breaking research presented in a Hot Line Session at this year’s ESC Congress 2024 in London, UK (30 Aug – 2 Sept).
StromaForte by Swedish StromaBio for Osteoarthritis: Likelihood of Approval – Pharmaceutical Technology
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes